The drugmaker's shares have lost 47% of their value from their three-year high and currently trade near a historically low ...

TIVDAK is approved for the treatment of recurrent or metastatic cervical cancer in the European Union, United States and Japan ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The rhetorical—if not yet real—decoupling between America and China, which business is afraid to speak out against, however ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Pfizer Inc. (NYSE:PFE)’s global commercial infrastructure could be used to maximize the potential of Seagen’s approved products and pipeline candidates, resulting in the acceleration of market ...

Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak ...